Strong start to FY26 with ₹875 Cr revenue; USFDA clearance, 20+ audits, and peptide lab expansion underline quality-first strategy
Bengaluru, 23 July 2025 , Syngene International Ltd. began FY26 with solid performance in the first quarter, reporting an 11% year-on-year increase in revenue from operations to ₹875 crore and a 59% surge in profit after tax (PAT) to ₹87 crore. The company’s reported EBITDA rose 19% to ₹224 crore, with margins improving to 25%.
Operational Growth: Research Services and Biologics Power Q1 Momentum
The strong financial delivery was driven by continued conversion of pilot programs into long-term contracts within the Research Services business and progress in biologics manufacturing. Syngene commenced operations at its new Unit III facility in Bengaluru and is advancing preparations to launch operations at its Bayview site in the United States later in the year.
Peter Bains, Managing Director and CEO of Syngene International Ltd., stated:
“We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. We have also made progress in scaling biologics and expanding scientific platform capabilities with a new peptide lab.”
Quality Milestones and Global Compliance
In Q1FY26, Syngene successfully completed a USFDA Good Clinical Practices (GCP) inspection of its Human Pharmacology Unit with no observations. Its Biologics facility at Biocon Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) outcome.
The company also concluded over 20 client and regulatory audits in the quarter, reinforcing its commitment to global compliance and operational transparency.
Scientific Expansion: Peptides & Platform Synergies
Syngene inaugurated a state-of-the-art dedicated peptide laboratory, enhancing its portfolio alongside monoclonal antibodies, Antibody-Drug Conjugates (ADCs), oligonucleotides, and PROTACs. Peptides are among the fastest-growing therapeutic modalities and strengthen Syngene’s integrated capabilities across development and manufacturing.
Deepak Jain, Chief Financial Officer, commented:
“This quarter’s revenue growth of 11% and improvement in EBITDA margins were driven by both topline momentum and cost optimization. We continue to maintain a robust balance sheet and will invest in technology to strengthen client offerings while staying focused on our annual guidance.”
Recognition for Sustainability
Syngene was named one of the World’s Most Sustainable Companies 2025 by TIME magazine and Statista. It ranked #1 in India’s pharma and biotech sector and within the top 20 globally in life sciences, chosen from a pool of over 5,700 organizations. This highlights Syngene’s strategic alignment with environmental stewardship and global ESG leadership.
Upcoming Investor Call
Syngene will host its Q1FY26 earnings call on July 24, 2025, at 12:15 PM IST, where senior management will discuss performance and outlook. Details for dial-in and webcast access are available on the company’s official website.
About Syngene International Ltd.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE) is a globally integrated research, development, and manufacturing services provider for pharmaceutical, biotech, nutrition, animal health, and specialty chemicals. With over 5,600 scientists and 2.5 million+ sq. ft. of infrastructure, Syngene supports 400+ clients including global leaders such as BMS, GSK, Zoetis, and Merck KGaA
